{
    "root": "143e1cd2-1b4f-4b78-bdbf-7ac83300e34c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TAKHZYRO",
    "value": "20250228",
    "ingredients": [
        {
            "name": "lanadelumab",
            "code": "2372V1TKXK"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        }
    ],
    "indications": "takhzyro\u00ae indicated prophylaxis prevent attacks hereditary angioedema ( hae ) adult pediatric patients aged 2 years older .",
    "contraindications": "subcutaneous . recommended : adult pediatric patients 12 years age older : administer 300 mg every 2 weeks patient caregiver . dosing interval every 4 weeks may considered patients . ( 2.1 ) pediatric patients 6 less 12 years age : administer 150 mg every 2 weeks healthcare provider caregiver . dosing interval every 4 weeks may considered patients . ( 2.2 ) pediatric patients 2 less 6 years age : administer 150 mg every 4 weeks healthcare provider caregiver . ( 2.2 ) full prescribing information instructions . ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "TAKHZYRO\u00ae is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.",
    "contraindications_original": "For subcutaneous use only. Recommended Dosage: Adult and pediatric patients 12 years of age and older: administer 300 mg every 2 weeks by the patient or caregiver. Dosing interval every 4 weeks may be considered in some patients. ( 2.1 ) Pediatric patients 6 to less than 12 years of age: administer 150 mg every 2 weeks by a healthcare provider or caregiver. Dosing interval every 4 weeks may be considered in some patients. ( 2.2 ) Pediatric patients 2 to less than 6 years of age: administer 150 mg every 4 weeks by a healthcare provider or caregiver. ( 2.2 ) See Full Prescribing Information for Administration Instructions. ( 2.3 )",
    "adverseReactions_original": "None."
}